| 名稱 | NCOA4-RET/BaF3 |
| 型號(hào) | CBP73265 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | NCOA4-RET/BaF3,母細(xì)胞：BaF3，凍存條件：90% FBS+10% DMSO |
產(chǎn)品搜索
相關(guān)文章
- 耳聾基因檢測標(biāo)準(zhǔn)品
- 老靶點(diǎn)迭代突破創(chuàng)新：Her2靶點(diǎn)細(xì)胞模型
- 潛力十足的T細(xì)胞療法，我們用得起嗎？
- GLP-1R、GCGR、GIPR多靶點(diǎn)激動(dòng)劑與代謝疾病
- ATCC細(xì)胞的培養(yǎng)方法
- 近期淋巴癌重磅級(jí)研究一覽
- 4-1BB（CD137）靶點(diǎn)藥物篩選模型
- 新型冠狀病毒：用于診斷的假病毒標(biāo)準(zhǔn)品和用于藥物研發(fā)的假病毒模型
- 腫瘤細(xì)胞調(diào)控關(guān)鍵因子和機(jī)制的研究講解
- 基于納米顆粒的組合免疫療法對致命性癌癥發(fā)起三重打擊
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73265NCOA4-RET/BaF3
- 詳細(xì)內(nèi)容
| CBP73265 | |
| I. Introduction | |
Cell Line Name： | NCOA4-RET/BaF3 |
Host Cell: | BA/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS1640+10%FBS |
Mycoplasma Status: | Negative |
| II.Background | |
NCOA4, nuclear receptor coactivator 4, is an androgen receptor coactivator (PMID: 15166229) and autophagy receptor that degrades ferritin complexes (PMID: 31061094) and plays a role in iron homeostasis (PMID: 30930742). NCOA4 fusions are frequently observed with RET in papillary thyroid carcinoma (also referred to as RET/PTC3) (PMID: 25731779) and have been reported in salivary intraductal carcinoma (PMID: 31162284), spindle cell tumors (PMID: 30938880), breast cancer (PMID: 30446652), colorectal cancer (PMID: 30210625), and lung cancer (PMID: 30038711). | |
| III. Representative Data | |
1. WB of NCOA4-RET/BaF3
| |
2. Anti-proliferation assay | |
Figure 2. CTG assay of for NCOA4-RET/BaF3 Stable Cell Line. | |
會(huì)員_a.png)